Project portfolio management: A powerful strategic weapon in pharmaceutical drug development

Drug Information Journal

Volumn 32, Issue 3, 1998, Pages 813-824

  Tiggemann, Rolf F ^a   Dworaczyk, David A ^b   Sabel, Hermann ^c  

^a C+C Pharma Consulting Ltd   (Germany)

^b Solvay Pharmaceuticals Inc   (Georgia)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Experience curve; Portfolio management principles; Project assessment; R and D portfolio management; Target profiling

Indexed keywords

DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; HEALTH ECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 0031823789     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159803200321     Document Type: Review

References (25)

1. Weber J, Hamilton JOC, Edmondson G, Dwyer P. Drug-merger mania, a rash of new alliances reshapes the industry. Business Week. May 16, 1994:30.
2. Weber J, Carey J, Hamilton JOC, Flynn J. Drugmakers are discovering the high cost of cutting costs. Business Week. October 17, 1994:204.
3. Higgins JC, Watts KM. Some perspective on the use of management science techniques in R&D management. R&D Management. 1986;16:291.
4. Fuld LM. Monitoring the competition. New York: John Wiley & Sons; 1988.
5. Spilker B. Multinational drug companies - issues in drug discovery and development. New York: Raven Press; 1989.
6. Berggren R, Teirlynck O. Managing the development portfolio. In Vivo. November 1995:10-16.
7. Cronrath C, Eckel R, Abshagen U. Portfolio analysis: A valuable tool for focusing R&D. Pharmaceutical Exec. September 1993:84-90.
8. Matheson JE, Menke MM, Derby SL. Managing R&D portfolios for improved profitability and productivity. J Sci Policy Res Management. 1989;4(4): 400-412.
9. Evans P. Streamlining formal portfolio management. Script Magazine. February 1996;25-28.
10. Nichols NA. Scientific management at Merck: An interview with CFO Judy Lewent. Harvard Bus Rev. January-February 1994:89-99.
11. Miliken FJ. Three types of perceived uncertainty about the environment. Acad Manage Rev. 1987; 12(1):133
12. Sounder WE. Managing new product innovations. Lexington, MA: Lexington Books; 1987.
13. Matheson D, Menke M, Keelin T, Holtzman S. Best practice decision-making in R&D. Script Magazine. July/August 1995.
14. Stolk J, Creagh S, Butz R. R&D vs. marketing: Bridging the twin towers. Pharmaceutical Exec. January 1992:54-62.
15. Matheson D, Matheson JE, Menke MM. Making excellent R&D decisions. Res Tech Manage. November-December 1994:21-24.
16. Matheson JE, Menke MM. Using decision quality principles to balance your R&D portfolio. Res Tech Manage. May-June 1994:38-43.
17. Balthasar HU, Boschi RAA, Menke MM. Calling the shots in R&D. Harvard Bus Rev. May-June 1994: 151-160.
18. Sabel H, Weiser C. Dynamics in marketing. Wiesbaden: Gabler; 1995.
19. Porter ME. Competitive advantage. New York: The Free Press; 1985.
20. Larson EW, Gobeli DH. Organizing for product development projects. J Prod Innov Man. 1988;5:180.
21. Ellul E, Reeves M. Decision quality: A key source of competitive advantage in drug development. In Vivo. February 1996:24-28.
22. DiMasi JA. Trends in drug development: Costs, times, and risks. Drug Inf J. 1995;29:375.
23. Kloock J, Sabel H, Schuhmann W. Erfahrungskurve und Unternehmenspolitik. ZfBetrw. 1987;87(2):3.
24. Tiggemann RF, Sabel H. An innovative concept in pharmaceutical drug development. Drug Inf. J. 1997; 31:119.
25. Katz R, Allen TJ. Project performance and the locus of influence in the R&D matrix. Acad Man J. 1985; 28(1):67.